# US 2019/0314400 A1 · Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314400 A1
- Document ID: US20190314400A1
- Status: Published application
- Kind: A1
- Application number: 16/386,522
- Filed: 2019-04-17
- Published: 2019-10-17
- Earliest claimed: 2010-04-07
- Assignees: California Institute of Technology
- Applicants: California Institute of Technology
- Inventors: Yue Shen; Sarkis K. Mazmanian
- Web page: https://patentgrep.com/patent/US20190314400A1

## CPC

- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/10: Dispersions; Emulsions
- A61K 39/0216: {Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08B 37/006: {Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- G01N 33/505: {involving T-cells}
- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55583: {Polysaccharides}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- G01N 2333/5428: IL-10
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method of treating an inflammatory disease or inflammation in an individual, comprising
administering an effective amount of a pharmaceutical composition comprising an outer membrane vesicle comprising a Polysaccharide A (PSA); and a pharmaceutically acceptable carrier,
wherein the composition is in the form of a tablet, granule, powder, solution, emulsion or suspension.

### Claim 26 (depends on 25)

The method of claim 25, further comprising identifying an individual suffering from an inflammatory disease or inflammation.

### Claim 27 (depends on 25)

The method of claim 25, wherein the inflammatory disease is inflammatory bowel disease (IBD).

### Claim 28 (depends on 27)

The method of claim 27, wherein treating IBD comprises reducing severity of one or more clinical IBD symptoms, reducing duration of one or more clinical IBD symptoms or reducing risk of developing a malignancy.

### Claim 29 (depends on 28)

The method of claim 28, wherein the malignancy comprises colon cancer.

### Claim 30 (depends on 25)

The method of claim 25, wherein the inflammatory disease is Crohn's disease.

### Claim 31 (depends on 25)

The method of claim 25, wherein the PSA is L-PSA.

### Claim 32

A method for directing the differentiation of a functional regulatory T cell (Treg) with potent suppressive activity, comprising
contacting dendritic cells with a pharmaceutical composition comprising an outer membrane vesicle of B. fragilis comprising a Polysaccharide A (PSA); and a pharmaceutically acceptable carrier,
wherein the composition is in the form of a tablet, granule, powder, solution, emulsion or suspension; and
wherein the composition programs the dendritic cells to induce differentiation of the Treg cell.

### Claim 33 (depends on 32)

The method of claim 32, wherein the PSA is L-PSA.

### Claim 34 (depends on 32)

The method of claim 32, wherein said Treg cell inhibits T cell activation.

### Claim 35 (depends on 32)

The method of claim 32, wherein the B. fragilis is a laboratory strain.

### Claim 36 (depends on 32)

The method of claim 32, wherein the B. fragilis is a mutant strain.

### Claim 37 (depends on 32)

The method of claim 32, wherein the B. fragilis is a mpi44 mutant.
